LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...
The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...
It’s September, which means the leaves are starting to change, pumpkin spice is back in everything, and the annual countdown to cold and flu season has officially begun. If you’re like most people, ...
Dr. Robert Malone — a member of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, a panel “that develops recommendations on the use of vaccines in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results